Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 785

1.

Improvement in resiliency factors among adolescents with neurofibromatosis who participate in a virtual mind-body group program.

Lester EG, Macklin EA, Plotkin S, Vranceanu AM.

J Neurooncol. 2020 Feb 20. doi: 10.1007/s11060-020-03441-8. [Epub ahead of print]

PMID:
32078086
2.

Corrigendum: Prion-Like Propagation of Protein Misfolding and Aggregation in Amyotrophic Lateral Sclerosis.

McAlary L, Plotkin SS, Yerbury JJ, Cashman NR.

Front Mol Neurosci. 2020 Jan 21;12:311. doi: 10.3389/fnmol.2019.00311. eCollection 2019.

3.

TNF receptor associated factor 6 interacts with ALS-linked misfolded superoxide dismutase 1 and promotes aggregation.

Semmler S, Gagné M, Garg P, Pickles SR, Baudouin C, Hamon-Keromen E, Destroismaisons L, Khalfallah Y, Chaineau M, Caron E, Bayne AN, Trempe JF, Cashman NR, Star AT, Haqqani AS, Durcan TM, Meiering EM, Robertson J, Grandvaux N, Plotkin SS, McBride HM, Vande Velde C.

J Biol Chem. 2020 Feb 6. pii: jbc.RA119.011215. doi: 10.1074/jbc.RA119.011215. [Epub ahead of print]

4.

The science of vaccine safety: Summary of meeting at Wellcome Trust.

Plotkin SA, Offit PA, DeStefano F, Larson HJ, Arora NK, Zuber PLF, Fombonne E, Sejvar J, Lambert PH, Hviid A, Halsey N, Garçon N, Peden K, Pollard AJ, Markowitz LE, Glanz J.

Vaccine. 2020 Feb 18;38(8):1869-1880. doi: 10.1016/j.vaccine.2020.01.024. Epub 2020 Jan 24.

PMID:
31987690
5.

Influenza Vaccines Delivered in Early Childhood Could Turn Antigenic Sin into Antigenic Blessings.

Worobey M, Plotkin S, Hensley SE.

Cold Spring Harb Perspect Med. 2020 Jan 21. pii: a038471. doi: 10.1101/cshperspect.a038471. [Epub ahead of print]

PMID:
31964642
6.

Virtual mind-body treatment for geographically diverse youth with neurofibromatosis: A pilot randomized controlled trial.

Lester E, DiStefano S, Mace R, Macklin E, Plotkin S, Vranceanu AM.

Gen Hosp Psychiatry. 2020 Jan - Feb;62:72-78. doi: 10.1016/j.genhosppsych.2019.12.001. Epub 2019 Dec 6.

PMID:
31841875
7.

Updates on immunologic correlates of vaccine-induced protection.

Plotkin SA.

Vaccine. 2020 Feb 24;38(9):2250-2257. doi: 10.1016/j.vaccine.2019.10.046. Epub 2019 Nov 22.

PMID:
31767462
8.

Prion-Like Propagation of Protein Misfolding and Aggregation in Amyotrophic Lateral Sclerosis.

McAlary L, Plotkin SS, Yerbury JJ, Cashman NR.

Front Mol Neurosci. 2019 Nov 1;12:262. doi: 10.3389/fnmol.2019.00262. eCollection 2019. Erratum in: Front Mol Neurosci. 2020 Jan 21;12:311.

9.

Cultivating resiliency in patients with neurofibromatosis 2 who are deafened or have severe hearing loss: a live‑video randomized control trial.

Greenberg J, Carter S, Lester E, Funes CJ, Macklin EA, Plotkin S, Vranceanu AM.

J Neurooncol. 2019 Dec;145(3):561-569. doi: 10.1007/s11060-019-03326-5. Epub 2019 Nov 1.

PMID:
31677033
10.

Is There a Correlate of Protection for Measles Vaccine?

Plotkin SA.

J Infect Dis. 2019 Nov 1. pii: jiz381. doi: 10.1093/infdis/jiz381. [Epub ahead of print] No abstract available.

PMID:
31674645
11.

CEPI: Driving Progress Towards Epidemic Preparedness And Response.

Gouglas D, Christodoulou M, Plotkin SA, Hatchett R.

Epidemiol Rev. 2019 Nov 1. pii: mxz012. doi: 10.1093/epirev/mxz012. [Epub ahead of print]

PMID:
31673694
12.

Infectious vaccine-derived rubella viruses emerge, persist, and evolve in cutaneous granulomas of children with primary immunodeficiencies.

Perelygina L, Chen MH, Suppiah S, Adebayo A, Abernathy E, Dorsey M, Bercovitch L, Paris K, White KP, Krol A, Dhossche J, Torshin IY, Saini N, Klimczak LJ, Gordenin DA, Zharkikh A, Plotkin S, Sullivan KE, Icenogle J.

PLoS Pathog. 2019 Oct 28;15(10):e1008080. doi: 10.1371/journal.ppat.1008080. eCollection 2019 Oct.

13.

Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.

Plotkin SR, Duda DG, Muzikansky A, Allen J, Blakeley J, Rosser T, Campian JL, Clapp DW, Fisher MJ, Tonsgard J, Ullrich N, Thomas C, Cutter G, Korf B, Packer R, Karajannis MA.

J Clin Oncol. 2019 Dec 10;37(35):3446-3454. doi: 10.1200/JCO.19.01367. Epub 2019 Oct 18. Erratum in: J Clin Oncol. 2020 Feb 20;38(6):656. J Clin Oncol. 2020 Feb 20;38(6):656.

PMID:
31626572
14.

Protective Immunity and New Vaccines for Lyme Disease.

Gomes-Solecki M, Arnaboldi PM, Backenson PB, Benach JL, Cooper CL, Dattwyler RJ, Diuk-Wasser M, Fikrig E, Hovius JW, Laegreid W, Lundberg U, Marconi RT, Marques AR, Molloy P, Narasimhan S, Pal U, Pedra JHF, Plotkin S, Rock DL, Rosa P, Telford SR, Tsao J, Yang XF, Schutzer SE.

Clin Infect Dis. 2019 Oct 17. pii: ciz872. doi: 10.1093/cid/ciz872. [Epub ahead of print]

PMID:
31620776
15.

Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma.

Gerstner ER, Emblem KE, Chang K, Vakulenko-Lagun B, Yen YF, Beers AL, Dietrich J, Plotkin SR, Catana C, Hooker JM, Duda DG, Rosen B, Kalpathy-Cramer J, Jain RK, Batchelor T.

Clin Cancer Res. 2020 Jan 1;26(1):206-212. doi: 10.1158/1078-0432.CCR-19-1739. Epub 2019 Sep 26.

PMID:
31558474
16.

Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells.

Pataer A, Ozpolat B, Shao R, Cashman NR, Plotkin SS, Samuel CE, Lin SH, Kabil NN, Wang J, Majidi M, Fang B, Roth JA, Vaporciyan AA, Wistuba II, Hung MC, Swisher SG.

Oncogene. 2020 Jan;39(4):801-813. doi: 10.1038/s41388-019-1010-4. Epub 2019 Sep 25.

17.

Emerging Developments in Targeting Proteotoxicity in Neurodegenerative Diseases.

McAlary L, Plotkin SS, Cashman NR.

CNS Drugs. 2019 Sep;33(9):883-904. doi: 10.1007/s40263-019-00657-9.

18.

A Rationally Designed Humanized Antibody Selective for Amyloid Beta Oligomers in Alzheimer's Disease.

Gibbs E, Silverman JM, Zhao B, Peng X, Wang J, Wellington CL, Mackenzie IR, Plotkin SS, Kaplan JM, Cashman NR.

Sci Rep. 2019 Jul 8;9(1):9870. doi: 10.1038/s41598-019-46306-5.

19.

Measles: Breakouts and Breakthroughs.

Plotkin SA.

J Pediatric Infect Dis Soc. 2019 Sep 25;8(4):289-290. doi: 10.1093/jpids/piz043. No abstract available.

PMID:
31282536
20.

Publisher Correction: Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI.

Ly KI, Vakulenko-Lagun B, Emblem KE, Ou Y, Da X, Betensky RA, Kalpathy-Cramer J, Duda DG, Jain RK, Chi AS, Plotkin SR, Batchelor TT, Sorensen G, Rosen BR, Gerstner ER.

Sci Rep. 2019 Jun 14;9(1):8721. doi: 10.1038/s41598-019-44365-2.

21.

First report of quality of life in adults with neurofibromatosis 2 who are deafened or have significant hearing loss: results of a live-video randomized control trial.

Funes CJ, Mace RA, Macklin EA, Plotkin SR, Jordan JT, Vranceanu AM.

J Neurooncol. 2019 Jul;143(3):505-513. doi: 10.1007/s11060-019-03182-3. Epub 2019 May 2.

PMID:
31049826
22.

Influenza in Latin America: A report from the Global Influenza Initiative (GII).

Gentile A, Paget J, Bellei N, Torres JP, Vazquez C, Laguna-Torres VA, Plotkin S; GII.

Vaccine. 2019 May 6;37(20):2670-2678. doi: 10.1016/j.vaccine.2019.03.081. Epub 2019 Apr 8. Review.

PMID:
30975568
23.

First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeutics.

Rauen KA, Alsaegh A, Ben-Shachar S, Berman Y, Blakeley J, Cordeiro I, Elgersma Y, Evans DG, Fisher MJ, Frayling IM, George J, Huson SM, Kerr B, Khire U, Korf B, Legius E, Messiaen L, van Minkelen R, Nampoothiri S, Ngeow J, Parada LF, Phadke S, Pillai A, Plotkin SR, Puri R, Raji A, Ramesh V, Ratner N, Shankar SP, Sharda S, Tambe A, Vikkula M, Widemann BC, Wolkenstein P, Upadhyaya M.

Am J Med Genet A. 2019 Jun;179(6):1091-1097. doi: 10.1002/ajmg.a.61125. Epub 2019 Mar 25.

PMID:
30908877
24.

From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis.

Ferner RE, Bakker A, Elgersma Y, Evans DGR, Giovannini M, Legius E, Lloyd A, Messiaen LM, Plotkin S, Reilly KM, Schindeler A, Smith MJ, Ullrich NJ, Widemann B, Sherman LS.

Am J Med Genet A. 2019 Jun;179(6):1098-1106. doi: 10.1002/ajmg.a.61112. Epub 2019 Mar 25.

PMID:
30908866
25.

How to Prepare for Expert Testimony on the Safety of Vaccination.

Plotkin SA.

Pediatrics. 2019 Apr;143(4). pii: e20183578. doi: 10.1542/peds.2018-3578. Epub 2019 Mar 6. No abstract available.

PMID:
30842258
26.

Chikungunya Virus: A Back-Breaking Problem.

Plotkin SA.

J Pediatric Infect Dis Soc. 2019 May 11;8(2):95-96. doi: 10.1093/jpids/piz012. No abstract available.

PMID:
30840767
27.

Dengue Vaccine, A Double-Edged Sword.

Plotkin SA.

J Pediatric Infect Dis Soc. 2019 Jan 18. doi: 10.1093/jpids/piy140. [Epub ahead of print] No abstract available.

PMID:
30657941
28.

A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.

Chen J, Landegger LD, Sun Y, Ren J, Maimon N, Wu L, Ng MR, Chen JW, Zhang N, Zhao Y, Gao X, Fujita T, Roberge S, Huang P, Jain RK, Plotkin SR, Stankovic KM, Xu L.

Nat Protoc. 2019 Feb;14(2):541-555. doi: 10.1038/s41596-018-0105-7.

29.

The National Vaccine Injury Compensation Program: Striking a Balance Between Individual Rights and Community Benefit.

Meissner HC, Nair N, Plotkin SA.

JAMA. 2019 Jan 29;321(4):343-344. doi: 10.1001/jama.2018.20421. No abstract available.

PMID:
30608524
30.

The changing epidemiology of mumps in a high vaccination era.

Marshall HS, Plotkin S.

Lancet Infect Dis. 2019 Feb;19(2):118-119. doi: 10.1016/S1473-3099(18)30541-3. Epub 2018 Dec 14. No abstract available. Erratum in: Lancet Infect Dis. 2019 Feb;19(2):e39.

PMID:
30558996
31.

CuATSM Protects Against the In Vitro Cytotoxicity of Wild-Type-Like Copper-Zinc Superoxide Dismutase Mutants but not Mutants That Disrupt Metal Binding.

Farrawell NE, Yerbury MR, Plotkin SS, McAlary L, Yerbury JJ.

ACS Chem Neurosci. 2019 Mar 20;10(3):1555-1564. doi: 10.1021/acschemneuro.8b00527. Epub 2018 Dec 7.

PMID:
30462490
32.

Ten yearly yellow fever booster vaccinations may still be justified.

Plotkin SA.

J Travel Med. 2018 Jan 1;25(1). doi: 10.1093/jtm/tay130. No abstract available.

PMID:
30462249
33.

Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI.

Ly KI, Vakulenko-Lagun B, Emblem KE, Ou Y, Da X, Betensky RA, Kalpathy-Cramer J, Duda DG, Jain RK, Chi AS, Plotkin SR, Batchelor TT, Sorensen G, Rosen BR, Gerstner ER.

Sci Rep. 2018 Nov 20;8(1):17062. doi: 10.1038/s41598-018-34820-x. Erratum in: Sci Rep. 2019 Jun 14;9(1):8721.

34.

Important New Resource for Clinicians Giving Expert Witness Testimony on Vaccines.

Plotkin SA, Offit PA, Reiss D.

Pediatr Infect Dis J. 2018 Dec;37(12):e353. doi: 10.1097/INF.0000000000002210. No abstract available.

PMID:
30408015
35.

Mind-Body Treatment for International English-Speaking Adults With Neurofibromatosis via Live Videoconferencing: Protocol for a Single-Blind Randomized Controlled Trial.

Vranceanu AM, Zale EL, Funes CJ, Macklin EA, McCurley J, Park ER, Jordan JT, Lin A, Plotkin SR.

JMIR Res Protoc. 2018 Oct 23;7(10):e11008. doi: 10.2196/11008.

36.

Prediction of Misfolding-Specific Epitopes in SOD1 Using Collective Coordinates.

Peng X, Cashman NR, Plotkin SS.

J Phys Chem B. 2018 Dec 13;122(49):11662-11676. doi: 10.1021/acs.jpcb.8b07680. Epub 2018 Nov 5.

PMID:
30351123
37.

Recommendations to control pertussis prioritized relative to economies: A Global Pertussis Initiative update.

Forsyth KD, Tan T, von König CW, Heininger U, Chitkara AJ, Plotkin S.

Vaccine. 2018 Nov 19;36(48):7270-7275. doi: 10.1016/j.vaccine.2018.10.028. Epub 2018 Oct 15. Review.

38.

pH dependent membrane binding of the Solanum tuberosum plant specific insert: An in silico study.

Dupuis JH, Yu H, Habibi M, Peng X, Plotkin SS, Wang S, Song C, Yada RY.

Biochim Biophys Acta Biomembr. 2018 Dec;1860(12):2608-2618. doi: 10.1016/j.bbamem.2018.10.001. Epub 2018 Oct 3.

39.

Lemons and Lyme.

Plotkin SA.

J Pediatric Infect Dis Soc. 2018 Dec 3;7(4):267-269. doi: 10.1093/jpids/piy083. No abstract available.

PMID:
30212842
40.

Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis.

Merker VL, Dai A, Radtke HB, Knight P, Jordan JT, Plotkin SR.

BMC Health Serv Res. 2018 Aug 29;18(1):668. doi: 10.1186/s12913-018-3471-5.

41.

Composition of pertussis vaccine given to infants determines long-term T cell polarization.

Plotkin SA.

J Clin Invest. 2018 Aug 31;128(9):3742-3744. doi: 10.1172/JCI122726. Epub 2018 Aug 6.

42.

Benign Intracranial Tumors.

Jordan JT, Plotkin SR.

Neurol Clin. 2018 Aug;36(3):501-516. doi: 10.1016/j.ncl.2018.04.007. Review.

PMID:
30072068
43.

Reply to Gantt et al., "Higher Expectations for a Vaccine To Prevent Congenital Cytomegalovirus Infection".

Permar SR, Schleiss MR, Plotkin SA.

J Virol. 2018 Jul 17;92(15). pii: e00771-18. doi: 10.1128/JVI.00771-18. Print 2018 Aug 1. No abstract available.

44.

Considerations for development of therapies for cutaneous neurofibroma.

Verma SK, Riccardi VM, Plotkin SR, Weinberg H, Anderson RR, Blakeley JO, Jarnagin K, Lee J.

Neurology. 2018 Jul 10;91(2 Suppl 1):S21-S30. doi: 10.1212/WNL.0000000000005791.

PMID:
29987132
45.

Cutaneous neurofibromas: Current clinical and pathologic issues.

Ortonne N, Wolkenstein P, Blakeley JO, Korf B, Plotkin SR, Riccardi VM, Miller DC, Huson S, Peltonen J, Rosenberg A, Carroll SL, Verma SK, Mautner V, Upadhyaya M, Stemmer-Rachamimov A.

Neurology. 2018 Jul 10;91(2 Suppl 1):S5-S13. doi: 10.1212/WNL.0000000000005792.

PMID:
29987130
46.

EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.

Angus SP, Oblinger JL, Stuhlmiller TJ, DeSouza PA, Beauchamp RL, Witt L, Chen X, Jordan JT, Gilbert TSK, Stemmer-Rachamimov A, Gusella JF, Plotkin SR, Haggarty SJ, Chang LS, Johnson GL, Ramesh V; Children’s Tumor Foundation Synodos for NF2 Consortium.

Neuro Oncol. 2018 Aug 2;20(9):1185-1196. doi: 10.1093/neuonc/noy046.

47.

The Influenza Vaccine Mess.

Plotkin SA.

J Pediatric Infect Dis Soc. 2018 Aug 17;7(3):178-180. doi: 10.1093/jpids/piy057. No abstract available.

PMID:
29982613
48.

Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.

Synodos for NF2 Consortium, Allaway R, Angus SP, Beauchamp RL, Blakeley JO, Bott M, Burns SS, Carlstedt A, Chang LS, Chen X, Clapp DW, Desouza PA, Erdin S, Fernandez-Valle C, Guinney J, Gusella JF, Haggarty SJ, Johnson GL, La Rosa S, Morrison H, Petrilli AM, Plotkin SR, Pratap A, Ramesh V, Sciaky N, Stemmer-Rachamimov A, Stuhlmiller TJ, Talkowski ME, Welling DB, Yates CW, Zawistowski JS, Zhao WN.

PLoS One. 2018 Jun 13;13(6):e0197350. doi: 10.1371/journal.pone.0197350. eCollection 2018.

49.

Portait of an ISV fellow.

Plotkin SA.

Hum Vaccin Immunother. 2018;14(8):1836-1839. doi: 10.1080/21645515.2018.1480199. Epub 2018 Jun 22. No abstract available.

50.

Resolving the phylogenetic origin of glioblastoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimens.

Brastianos PK, Nayyar N, Rosebrock D, Leshchiner I, Gill CM, Livitz D, Bertalan MS, D'Andrea M, Hoang K, Aquilanti E, Chukwueke UN, Kaneb A, Chi A, Plotkin S, Gerstner ER, Frosch MP, Suva ML, Cahill DP, Getz G, Batchelor TT.

NPJ Precis Oncol. 2017 Sep 18;1(1):33. doi: 10.1038/s41698-017-0035-9. eCollection 2017.

Supplemental Content

Loading ...
Support Center